Skip to main content

Table 3 Univariate analysis for local control (LC) and overall survival (OS)

From: Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors

Variables UVA for LC UVA for OS
  HR (95% CI) P value HR (95% CI) P value
Age (per 10-y increase) 0.95 (0.80-1.15) 0.617 0.93 (0.80-1.11) 0.428
Gender (female vs. male) 0.66 (0.34-1.19) 0.177 0.53 (0.33-0.83) 0.005*
Performance status (0–1 vs. ≥ 2) 1.19 (0.52-3.43) 0.703 0.86 (0.50-1.58) 0.619
Tumor origin (primary lung cancer vs. metastatic lung tumors) 0.48 (0.27-0.87) 0.017* 0.53 (0.34-0.84) 0.007*
History of other malignancies (yes vs. no) 0.70 0.38-1.21) 0.212 0.83 (0.56-1.20) 0.331
Pack-year smoking (≥ 37.5 vs. < 37.5) 1.38 (0.77-2.51) 0.266 0.85 (0.57-1.26) 0.426
Operability (operable vs. inoperable) 0.68 (0.38-1.19) 0.185 0.76 (0.52-1.12) 0.173
FEV1, % of predicted (≥ 92% vs. < 92%) 1.01 (0.49-2.05) 0.972 0.84 (0.51-1.36) 0.494
Tumor diameter (per 1 cm increase) 1.87 (1.35-2.57) <0.001* 1.70 (1.33-2.16) <0.001*
SUVmax (≥ 5.9 vs. < 5.9) 2.21 (1.02-5.03) 0.042* 2.12 (1.26-3.64) 0.004*
Date of treatment (2001–2005 vs. 2006–2011) 1.91 (1.11-3.39) 0.019* 1.36 (0.93-1.99) 0.106
Prescription dose (BED10: > 105 Gy vs. ≤ 105 Gy) 0.56 (0.32-0.96) 0.038* 0.94 (0.65-1.37) 0.760
Radiation pneumonitis (≥ 2 vs. < 2) 0.85 (0.34-1.78) 0.689 0.72 (0.40-1.22) 0.225
  1. Abbreviations: UVA univariate analysis, LC local control, OS overall survival, HR hazard ratio, CI confidence interval, FEV1 forced expiratory volume in 1 second, SUVmax maximum standardized uptake value, BED10 biological effective dose calculated using α/β = 10. *p < 0.05.